Gastric stimulation for weight loss

被引:20
作者
Mizrahi, Meir [1 ,2 ]
Ben Ya'acov, Ami [1 ,2 ]
Ilan, Yaron [1 ,2 ]
机构
[1] Hebrew Univ Hadassah Med Ctr, Gastroenterol Unit, Jerusalem, Israel
[2] Hebrew Univ Hadassah Med Ctr, Liver Unit, Jerusalem, Israel
关键词
Obesity; Gastric stimulation; Gastric motility; External pacing; Gastric pacing; Intestinal pacing; GLUCAGON-LIKE PEPTIDE-1; REDUCES FOOD-INTAKE; PLASMA GHRELIN LEVELS; ELECTRICAL-STIMULATION; MORBID-OBESITY; ARCUATE NUCLEUS; POSTPRANDIAL CONCENTRATIONS; ACYLATED PEPTIDE; LEPTIN RECEPTOR; GUT HORMONE;
D O I
10.3748/wjg.v18.i19.2309
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The prevalence of obesity is growing to epidemic proportions, and there is clearly a need for minimally invasive therapies with few adverse effects that allow for sustained weight loss. Behavior and lifestyle therapy are safe treatments for obesity in the short term, but the durability of the weight loss is limited. Although promising obesity drugs are in development, the currently available drugs lack efficacy or have unacceptable side effects. Surgery leads to long-term weight loss, but it is associated with morbidity and mortality. Gastric electrical stimulation (GES) has received increasing attention as a potential tool for treating obesity and gastrointestinal dysmotility disorders. GES is a promising, minimally invasive, safe, and effective method for treating obesity. External gastric pacing is aimed at alteration of the motility of the gastrointestinal tract in a way that will alter absorption due to alteration of transit time. In addition, data from animal models and preliminary data from human trials suggest a role for the gut-brain axis in the mechanism of GES. This may involve alteration of secretion of hormones associated with hunger or satiety. Patient selection for gastric stimulation therapy seems to be an important determinant of the treatment's outcome. Here, we review the current status, potential mechanisms of action, and possible future applications of gastric stimulation for obesity. (c) 2012 Baishideng. All rights reserved.
引用
收藏
页码:2309 / 2319
页数:11
相关论文
共 121 条
  • [1] IDIOPATHIC CYCLIC NAUSEA AND VOMITING - A DISORDER OF GASTROINTESTINAL MOTILITY
    ABELL, TL
    KIM, CH
    MALAGELADA, JR
    [J]. MAYO CLINIC PROCEEDINGS, 1988, 63 (12) : 1169 - 1175
  • [2] HUMAN DISTRIBUTION AND RELEASE OF A PUTATIVE NEW GUT HORMONE, PEPTIDE-YY
    ADRIAN, TE
    FERRI, GL
    BACARESEHAMILTON, AJ
    FUESSL, HS
    POLAK, JM
    BLOOM, SR
    [J]. GASTROENTEROLOGY, 1985, 89 (05) : 1070 - 1077
  • [3] Pilot acute study of feedback-controlled retrograde peristalsis invoked by neural gastric electrical stimulation
    Aelen, P.
    Jurkov, A.
    Aulanier, A.
    Mintchev, M. P.
    [J]. PHYSIOLOGICAL MEASUREMENT, 2009, 30 (03) : 309 - 322
  • [4] What can bariatric surgery teach us about the pathophysiology of type 2 diabetes?
    Andreelli, F.
    Amouyal, C.
    Magnan, C.
    Mithieux, G.
    [J]. DIABETES & METABOLISM, 2009, 35 (06) : 499 - 507
  • [5] Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin
    Asakawa, A
    Inui, A
    Kaga, T
    Yuzuriha, H
    Nagata, T
    Ueno, N
    Makino, S
    Fujimiya, M
    Niijima, A
    Fujino, MA
    Kasuga, M
    [J]. GASTROENTEROLOGY, 2001, 120 (02) : 337 - 345
  • [6] Biology of incretins: GLP-1 and GIP
    Baggio, Laurie L.
    Drucker, Daniel J.
    [J]. GASTROENTEROLOGY, 2007, 132 (06) : 2131 - 2157
  • [7] Gut hormone PYY3-36 physiologically inhibits food intake
    Batterham, RL
    Cowley, MA
    Small, CJ
    Herzog, H
    Cohen, MA
    Dakin, CL
    Wren, AM
    Brynes, AE
    Low, MJ
    Ghatei, MA
    Cone, RD
    Bloom, SR
    [J]. NATURE, 2002, 418 (6898) : 650 - 654
  • [8] Inhibition of food intake in obese subjects by peptide YY3-36
    Batterham, RL
    Cohen, MA
    Ellis, SM
    Le Roux, CW
    Withers, DJ
    Frost, GS
    Ghatei, MA
    Bloom, SR
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (10) : 941 - 948
  • [9] Vagal and hormonal gut-brain communication: from satiation to satisfaction
    Berthoud, H. -R.
    [J]. NEUROGASTROENTEROLOGY AND MOTILITY, 2008, 20 : 64 - 72
  • [10] Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes
    Blonde, L.
    Klein, E. J.
    Han, J.
    Zhang, B.
    Mac, S. M.
    Poon, T. H.
    Taylor, K. L.
    Trautmann, M. E.
    Kim, D. D.
    Kendall, D. M.
    [J]. DIABETES OBESITY & METABOLISM, 2006, 8 (04) : 436 - 447